Tenpoint Therapeutics has submitted a New Drug Submission to Health Canada seeking approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) for the treatment of presbyopia in adults.
The Canadian submission is supported by results from BRIO I and BRIO II, two randomized, double-masked, controlled phase 3 studies. According to Tenpoint, the studies demonstrated statistically significant improvements in near vision following once-daily administration. The treatment produced miosis beginning at 30 minutes and lasting up to 10 hours. The company reported no treatment-related serious adverse events during more than 72,000 dosing days monitored in BRIO II.
The once-daily eye drop is the first dual-agent ophthalmic solution approved in the United States for presbyopia, receiving US Food and Drug Administration approval in January 2026. It has since received limited authorization for use at a hospital in China’s Hainan province. Tenpoint has also entered a licensing agreement for potential commercialization in several European markets.


